Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a ...

AbbVie’s ABBV immunology franchise remained the company’s biggest growth driver in the first quarter of 2026, which beat ...

In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week 16.

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL-17 ...

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...

Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology megablockbuster Humira, CEO Robert Michael can now declare that “we have never been in a ...

Skyrizi is a biologic medication used to treat several inflammatory conditions, including Crohn’s disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis, in adults. Dosage typically ...

People with Crohn’s disease often take medicines to help manage their condition and improve their symptoms. Some of these medicines are taken by mouth and stay inside of the digestive tract. But ...